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There is considerable evidence now suggesting that glutamate may mediate the neurotoxicity observe d in hypoxicischemic brain injury. Several source s of data support this hypothesis: (i) glutamate produces neurona l injury similar to that observed after cerebra l hypoxia-ischemia; (ii) elevated extracellu lar levels of glutamate and aspartate are present during cerebral ischemia; (iii) excitatory deafferentation results in improved neuronal survival; and (iv) NMDA receptor an-tagonists exhibit neurop rotective effects under a varie ty of experim ental conditions (1) (2) (3) (4) . Although NMDA antagonists may be of therapeutic value in severa l forms of acute brain injury , the pharmacology of these compo unds is complex, and their effects on the developing anima l are not always pred ictable. For example, MK-801 is a powerful NMDA receptor antagoni st with high efficacy in preventing hypoxic-ischemic brain injury in the infant rat model (5) . However, under certain circumstances, acute administration of MK-801 to postnata l d 7 rats results in up-regulation of the number of NMDA receptors and a parad oxical enhancement of the NMDA-mediated brain injury as MK-801 levels dimini sh in the brain (6) . A number of factors may influence the extent of brain injury after 645 ischemia, including changes in CBF. There is now ev idence that NO participates in regulation of the cerebral circulation (7) . However, the role of NO during cerebral ischemia is poorly understood. Acute administration of NO inhibitors have been reported to be either protective (7, 8) or deleterious (7, 9) during foc al cerebral ischemia. Little information is ava ilable regarding the hemodynamic effects of NMDA and NO synthase antagonists in the neon atal animal, and w hether the protective effects of these agents are in part due to alterations in regional hemodynamics.
In the current stud y, we compare the effects of a noncompetitive NMDA receptor antagonist, MK-801 , and a NO synthase inhibitor (L-NAME) on focal excit otoxic brain injury and the associ ated hemodynamic response in the newborn lamb model. Our hypothesis is that focal lesions and hemodynamic disturbances associated with intrastrial injection of NMDA are receptor-mediated and modulated by NO .
We chose the neon atal lamb as our model for the following reasons. I ) The size and developmental features of neonatal lamb brain more closely approximate those of the full-t erm infant co mpared with the neonatal rodent brain. Regional blood flow studies and sonographi c characteriz ation of excitotoxic lesions would not be possible in sm aller rodent species. 2) Fetal and neonatal lamb brain has been extensively used as a model for the study of hypo xic-ischemic brain injury (10-13).
3) NO sy nthas e is expre ssed in high levels throughout the 1-7-d-old newborn lamb brain (14) (15) .
METHODS
Twent y-eight mixed breed newborn lamb s (me an age 4.2 d, range 1-7 d) were anesthetized with i.v. pentobarbital (12-15 mg/kg loading dose ; 3 mg/kg/h continuous drip) , intub ated, and me chanically ventilated using a Harvard pump resp irator (Harvard Apparatus, Dov er, MA). Cor e body (rectal) temperature was monitored and maintained between 37 and 38°C in every anim al. The eye blink reflex, pedal reflex , and withdrawal from pain were used to document adequa te anes thes ia. Pol yvin yl catheters (Martech Medical Products, Harlysville , PA) we re placed in the right femoral artery for con tinu ous blood pressure monitoring, and right femoral vein for administration of i.v. fluids and medication s in every anim al. In lamb s in which CBF determ inations were obtained, additional catheters were placed in the left ventricle (via the right brachiocephalic artery) for injection of radiolabeled microspheres, the left axillary artery for obtaining microsphere refer ence samples, and sag ittal sinus for obtaining mixed cerebral venous blood gases. A 1 X 5-cm transverse bone flap was rem oved acro ss the midline, approxi mately 1.5 em anterior to the lambda. Thi s bony window was used for sonographic access and for plac ement of a sagittal sinu s catheter.
Th e anim als were divid ed into one con trol group and three experimental groups each containing seven animals. In every lamb, a 27 gauge needle was placed into the right striatum, using a stereotactic device, and under direct sonographic visualization. Control animals received 0.2 mL of 0.1 M PBS (pH 7.4) to assess the indi vidu al effects of intracerebral inje ction a lone :-~ll other animals received 5 urn ol of NMDA in 0.2 mL of buffered salin e. Each intracerebr al injection was performed over 2 min, and the needle was left in place for an additional 2 min before rem oval. The first ex perimental group received the intracerebral injection of NMDA without pretreatment. The two rem aining exp erim ental groups were pretreated with either a noncompetitive NMDA receptor antagonist (MK-80 1, 5 mg/ kg), or L-NA ME (60 mg/kg), a NO sy nthase inh ibitor, each give n 60 min before intracerebral injection of NMDA. These doses were determined by review of pertin ent ex perimental literatur e (16) (17) (18) .
Sonographic guid ance for needl e plac ement wa s performed using a high resolution computerized ultrasound un it (ACU-SON 128 XP, Mountainview, CA) , equipped with a vector 7.0 MHz transducer. Serial images were obtained in coronal projection before and after intracerebral injection using a 7.0 MHz linear transducer. Th e image was magnified so that it filled the ent ire scre en. Imaging parameters we re set to maximize the dynamic range of the image. Frame ave raging was se t at a persisten ce setting of 4, a mod erate edge-enhancing fun ction wa s selec ted (prep rocessing setting 1), and the log compression was set at 53 dB. The greatest dimen sion of each lesion was measured in the x, y, and z axis on sonographic images , and the volume estimated by the formula fo r volume of an ellipsoid
CBF determinations were obtained in four of seven lambs from each group using the radiol abeled microsphere technique (19) . We used six different microsph eres measur ing 16 :t 0.5 p,m in diameter, each labeled with one of the following isotop es, 1141n, 113Sn, 103Ru, 95Nb, 46SC, and 153Gd, and suspend ed in a solution containing approxi mately 1.4 X 10 6 microspheres in each vial (Dupont, Boston , MA). Th e microsph eres were cho sen in random ord er, and 0.4 mL was injected over 45 s into the left ventricular catheter. A reference blood sample was simultaneously withdrawn from the axillary artery at a rate of 2.5 mLimin over 1 min with a calibrated syringe (Harv ard Apparatus, Dover, MA ). Withdrawal rates were confirmed by weighing the sy ringe before and after obtaining the reference sample and by timin g the withdrawal interval with an electronic tim er. Ti ssue and reference blood sa mples were counted in a deep we ll gamma count er (Packard Instruments , Downers Groves, IL). Right and left diencephalon , midbrain, caud ate nucleus, and cerebellum were separated from other structures and submitted for radio activity me asurements as wh ole structures. Regional CBF (mLimin/100 g of brain tissue) wa s determined for each of the above structures, as well as for total brain and each cere bral hemisphere. A weighted average of individual radioactivit y measur ements (expressed per 100 g of tissue) was used to derive regional CBF for total brain and ce rebral hemispheres. Regional CVR (mm Hg/m Limin/lOO g) was determined for total brain and right and left hemi sph eres .
Estimates of cerebral metabolism. Cerebral hemispheric oxygen extraction was calculated using the formul a (Cao., -Cvoz)/Ca o z, where Cao, is arteri al oxygen content, and Cvo., is mix ed cerebral venous oxygen cont ent. Oxygen co ntent was calculated by the formula: (Po z X 0.003) + (Hb [g] X 1.34 X %Oz saturation). Cerebr al hemisph eric oxygen consumption (mL of Oz/mLimin/lOO g) was calcul ated by the formula CBF 646 TAYLOR ET AL.
(Cao, -Cvoj) , where CBF is blood flow to the cerebral hemispheres in mL/min/100 g of brain.
Mean arterial blood pressure and pulse pressure were continuously monit ored using a multichannel record er (Gould Instruments, Ormand CA). Arterial and mixed venous (sagitt al sinus) pH, Pco, and P0 2 were measured at 39.5°C using a Radiometer ABL 30 (Radiometer, Cleveland, OH), Oxygen saturation and Hb were measured using the Hemoximeter OSM2 (Radi ometer) calibrated for lamb's blood.
CBF determinations, blood pressure, and arterial and sagitt al sinus blood gases were obtained at baseline, after a 3D-min equilibration period after surg ery, 60 min after i.v. injection of MK-801, or L-NAME, and at 20, 40, and 60 min after intracerebral injection of buffered saline, or NMDA.
The animals were killed 70-80 min after NMDA inject ion with an i.v. overdose of pentobarbital and saturated potassium chloride.
Experimental, anesthesia, and euthanasia protocols were approved by The Johns Hopkins University Institutional Animal Care and Use Committee, and are consistent with the recommendations of the Ame rican Veterin ary Medical Association.
Cath eter placement was verified at autopsy, and the brain was removed for micros phere analysis (n = 16). CBF determinations were not performed in 12 animals (three from each group). In these animals, the brain was removed and prese rved in 10% form alin for 10-14 d. Each specimen was then sectioned in standard coronal projection , and the location and size of the lesion was correlated with the appearance on sonography. Histologic sections were obtained through the basal ganglia and stained with hemato xylin and eosin .
Data analysis. The sonographic feature s for each lesion studied were described and correlated with gro ss and histologic appearance on pathologic exa mination. Animals receivmg NMDA antagonists or L-NAME were comp ared with those animals not receiving pretreatment with respect to change s in histologi c characteristics, and average size of NMDA-induced lesions . Both absolute and relative changes in regional CBF (expressed as % change from baseline) were used for analysis. Differences in CBF, cerebro vascul ar resist ance, and other physiologic variables at each interval were analyzed using a two-way repeated measures ANOVA. Comp arisons of CBF among treatment groups at each interval, as well as lesion size among treatment groups were performed using a factori al ANOVA. All values are expressed as ±SEM.
RESULTS
Sono graphic lesions consist ed of well defined areas of increased echogenicity and ranged in volume from < 0.7 to 203 mnr'. When present, focal lesions could be identified on real time sonography, within 30-60 s after intracerebral injection, and did not change in size thereaft er until the end of the experiment.
In the negati ve control (buffered salin e), intracerebral lesion s were detected in 71% of animals, with a mean lesion size of 13.6 ± 5 mm' , In the positiv e control (untreated NMDA) group, lesions we re observed in every animal , and mean lesion size (92.9 ± 24 mrrr') was larger than in saline-injected animals (p < 0.007). Pretreatment with MK-801 reduced the frequency (57 %) and mean size (11.7 ± 6 mrrr') of NMDAinduced lesions (p < 0.05 for both comparisons), whereas pretreatment with L-NAME resulted in no effect on either lesion frequency (93 %) or size (69.9 ± 20 mrrr', p = 0.46) comp ared with untreated NMDA injecti on (Fig. 1) . . . ,, ' -, widespread and symmetric throughout both hemispheres, cerebellum, medulla, and pons. Similarly, supratentorial CVR decreased from 1.2 ± 0.1 to 0.53 ± 0.1 Hg/mLimin/lOO g after injection (p = 0.0001). There was no difference in percent change in CBF between both hemispheres at any interval after NMDA injection (p > 0.27 by 2-tailed paired t test).
Although a transient increase in mean blood pressure was seen during L-NAME administration, neither MK-801 or L-NAME had an effect on supratentorial blood flow 60 min after the pretreatment dose and before intracerebral NMDA injection (p < 0.1 by ANOVA).
Pretreatment with MK-801 resulted in near complete ablation of the hyperemic response to NMDA injection. Mean CBF to the midbrain, diencephalon, cerebellum, pons, medulla, and cerebral hemispheres, and supratentorial CVR were unchanged after NMDA injection (p > 0.5). Animals pretreated with L-NAME showed an asymmetric hemodynamic response to NMDA injection. CBF in areas closest to the injection site (ipsilateral midbrain and diencephalon) increased (p < 0.04) and was indistinguishable from that observed in untreated NMDA injection (p > 0.25). In the ipsilateral cerebral hemisphere, hyperemia was present, but less than found in untreated Size and contour of focal brain lesions noted on ultrasound correlated well with gross pathologic findings (Fig. 2) . Histologically, the NMDA lesions were characterized by focal areas of petechial hemorrhage, with shrinkage and triangulation of the nucleus and cytoplasm, and microvacuolization consistent with early neuronal injury (Fig. 3 ). There were no histologic differences in type of injury among the animals receiving pretreatment with MK-801 or L-NAME. Only small hemorrhagic foci were detected in the three animals injected with buffered saline (Fig. 4) . Figure 5 shows changes in regional CBF before and after intracerebral injection of buffered saline or NMDA, respectively.
Intracerebral injection of buffered saline (negative control) was not associated with any significant regional or global hyperemia after injection. Supratentorial CBF was 61 ± 8, 66 ± 14,47 ± 7, and 58 ± 7 mLimin/100 g before, and 20, 40, and 60 min after saline injection (p > 0.5). Hemispheric CVR also remained unchanged, ranging between 1.2 ± 0.1 and 1.8 ± 0.2 mm Hg/mLimin/lOO g before and after saline injection.
Injection of NMDA (positive control), however, resulted in regional and global hyperemia involving both hemispheres. The most marked elevation in CBF was seen in ipsilateral midbrain (p = 0.0006 by ANOVA). Increased CBF was hemisphere, however, was completely ablated, with both CBF and CVR remaining unchanged. Although these animals showed a tendency toward higher supratentorial CBF, it only approached statistical significance (p < 0.06).
Within each treatment category, there was no correlation between lesion size and percent change in regional or global CBF.
Physiologic measurements obtained for each experimental group are presented in Table 1 . Hemispheric cerebral metabolic rate (cerebral oxygen consumption), mean arterial blood pressure, Hb, Pc0 2 , and O 2 content were not affected by saline or NMDA injection with or without pretreatment. A significant metabolic acidosis was observed at 20 and 40 min after NMDA injection in animals receiving NMDA only. This was associated with a trend toward decreasing mean arterial blood pressure, suggesting a lactic acidemia due to systemic underperfusion.
DISCUSSION
In the current study, intrastrial injection of NMDA resulted in focal lesions with histologic characteristics of early infarction and generalized cerebral hyperemia. These data confirm our previous findings on the histologic and hemodynamic effects of intrastrial NMDA injection (20) . The new findings of this study are that pretreatment with MK-801 attenuated both Hb (g) NaC I
9.8 ± 0.4 9.2 ± 0.3 9.6 ± 0.2 9.7 ± 0. Physiologic variables at baseline and before and after intrastriatal injection were comp ared by ANOV A. Baseline : initial measurements befor e pretreatment with MK-801 or L-NAME. Posttr eatme nt: measurements obtained after pretreatment with MK-80 1 or L-NAME, and before intrastriata l injection . Thi s measure represents a seco nd baseline measure in anima ls not receiving pretreatment. BP, mean arterial blood pressure ; pH , arter ial pH; Hb, arterial hemo globin ; A -O z , arterial oxygen content; Pco z, arterial partial press ure COz (kilopascal s); CMRoz, cerebral oxy gen consumption . lesion frequency and volume, and completely ablated the hyperemic cerebrovascular response, whereas L-NAM E appeared to have no neuroprotective effects, and only ablated cerebral hyperemia in the hemisph ere contralateral to the NMDA injection site.
The efficacy of MK-801 as a neuroprotective agent has been well documented in both ischemic, and in NMDA-induced models of brain injury using adult animals (3, 16, 21, 22) . Its effects on the cerebral vasculature, however, appear to be quite variable and dependent on species and experimental model used. In normal dogs, for example, MK-801 increases CBF, but appears to have no hemodynamic effect when given after an episode of complete cerebra l ischemia (23) . Conversely, in the rat model, it reduces regional CBF in the cerebral hemisphere contralateral to middl e cerebral artery occlusion (24) . In rabbits, MK-801 attenuates postischemic hypoperfusion in the penumbral region of brain after middle cerebral artery occlusion (25) . In addition, cerebrovascular effects of MK-801 may be modified by anesthesia. MK-801 increases hemispheric CBF in conscious rats, but results in no change or a decrease in CBF in the a-chloralose-anesthetized rat (26) . In the current study, using pentobarbital-anesthetized lambs, pretreatment with MK-801 appeared to completely block cerebral hyperemia indu ced by intrastrial NMDA injec tion. These data strongly suggest that both the neuron al injury and associated hyperemic respo nse in this model are NMDA receptormediated pheno mena.
There are three potential mecha nisms by whic h NMDA receptor antagonists may inhibit vasodi latation: by a direct effect on cerebral resistance vessels, by increasing cerebral oxidative metabolism, and by altering production of a second vasodilatory substance.
A direct effect on the cerebral vasculature is unlikely, because NMDA receptor complexes have not been demonstrated in sheep microvessels (27) . It is possib le that, in the current study, a small amount of NMDA may have leaked along the needle tract to the surface of the brain. However, it is unlikely that arterioles deep within the contralateral hemisphere, or in infratentorial structures, were exposed directly to injected NMDA.
A second mechanism by which MK-801 may exert its hemodynamic effect is by inhibiting the release of a second vasodilatory substance such as NO. NO is known to exert potent vasodi latory effects on the cerebral circulation (11, 12, 22, 23) . NMDA receptor activation has been associated with an increase in intracellular NO levels in rat brain slices (28, 29) and in the somatosens ory cortex during peripheral nerve stimulation. These changes can be uncoupled by the introduction of an inhibitor of NO synthase (30) . Using microdialisis techniques, Northington and Traystm an (31) have shown that the elevation of regional CBF and NO production associated with intracereb ral perfusion with NMDA is ablated by adding L-NAME, a potent NO synthase enzyme inhibitor.
TAYLOR ET AL.
During foca l cerebral ischemia, a sharp, transient increase in NO occurs with subsequent activation of guanylate cyclase (32) . However, it is not clear whether NO enhanc es or serves as a protective influence on glutamate-mediated neurotoxicity (8) . Alth ough Demerl e-Pallardy et al. (9) showed no change in neuron al injury produced by t-glutarnate or hypoxia when brain cells were treated with L-NAME , Nowicki et at. (28) showed that inhibition of NO produ ction resulted in a dramatic 72% reduction in infarct volume . Similarly, Dawson et al. (33) showed mediation of glutaminergic neurotoxicity by NO via NMDA receptors in cerebral cortical cultures. These disparate results may be due to the nonselective blockade of endothelial, neuronal, and inducible NO synthase by L-NAME. In a study using mice deficient in neuronal NO synthase, Huang et al. (34) have shown a reduction in infarct size after middle cereb ral artery occlu sion in mice deficient in neuronal NO synthase compared with wild-type mice. When these mutant mice were treated with L-NAME to inhibit endothelial NO synthase, infarct size increased to baseline levels (34) . In the current study, pretreatment with L-NAM E resulted in no neuroprotective effect and a strikingly asymmetric CBF response. Although there was no reduction in hyperemia in the ipsilateral hemisphere, there was complete ablation of this response in the contralateral side. The dose of L-NAME used in this study (60 mg/kg, i.v.) is within the range demonstrated to result in > 90% inhibiti on of NO synthase for 1-30 h after administration (32) . It is possible that direct intrastrial injec tion of NMDA resulted in incomplete inhibition of NO synthase in areas of brain closer to the injection site and a differential effect on the cerebral vasculature.
A third potential mechanism is inhibition of neuronal overstimulation by NMDA and accompanying vasodilatation (35, 36) . This may be due in part to intra-and extracellular acidosis associat ed with neuronal injury and the likely disruption of oxida tive metabolism produced by NMDA overstimul ation. There are abundant fiber interconnecti ons throughout the basal ganglia that form part of complex reciprocating circuits with the cerebral cor tex and thalamu s. Overstimul ation of neurons in the basal ganglia (striatum) by injected NMDA may result in excitation and subsequent vasodilatation in other remote regions receiving afferent input from these areas. Postsynaptic NMDA receptors exist on catecholaminergic neurons containing NO synthase. Thus, NO produced by these cells may act as a spatial signal to facilitate the release of neurotransmitters from surrounding synapses (37, 38) . Therefore, either inhibition of neuronal overstimulation by MK-801 or inhibition of neuron al NO synthase by L-NAME would result in at least partial attenuation of hyperemia. This explanation would be consistent with our findings of asymmetric suppression of cerebral hyperemia by L-NAME only in the contralateral hemisphere.
Althou gh the exac t mechanisms by which NMDA induces cerebral hyperemia remain unclear, the results of this study stron gly suggest that these effect s are NMD A recept ormediat ed phenomena and that NO production may not playa major part in NMDA-induced neuron al injury in the newborn animal. The consistent strong neurop rotective effects of MK-801 despite its widely variable hemodynamic effects on various experimental animal models make it unlikely that the neuroprotective and hemodynamic effects of this compo und are related (24) . The findings in this study should be extrapolated to ischemic condit ions cautiously, because the vasc ular effects of MK-801 may be different in ischemic and nonischemic tissues.
